949527-46-2

Basic information

• Product Name: 4-chloro-6-(4-methoxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine
• Synonyms: 4-chloro-6-(4-methoxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine
• CAS NO: 949527-46-2
• Molecular Weight: 358.872
• Mol File: 949527-46-2.mol

Chemical Properties

• CAS DataBase Reference: 4-chloro-6-(4-methoxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-(4-methoxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine(949527-46-2)
• EPA Substance Registry System: 4-chloro-6-(4-methoxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine(949527-46-2)

Safety Data

• Hazardous Substances Data: 949527-46-2(Hazardous Substances Data)

Upstream product

• 5703-26-4 4-Methoxyphenylacetaldehyde 
• 949527-44-0 2-amino-5-(4-methoxyphenyl)thiophene-3-carboxylic acid ethyl ester 

Downstream Products

• 949527-47-3 4-chloro-6-(4-hydroxyphenyl)-2-(thiophen-2-yl)thieno[2,3-d]pyrimidine 

Relevant articles and documents

Structural modifications at the 6-position of thieno[2,3- d ]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia

Fms-like tyrosine kinase 3 (FLT3) is a well-known and important target for the treatment of acute myeloid leukemia (AML). A series of thieno[2,3-d]pyrimidine derivatives from a modification at the 6-position were synthesized to identify effective FLT3 inhibitors. Although compounds 1 and 2 emerged as promising FLT3 inhibitors among the synthesized compounds, both compounds exhibited poor metabolic stability in human and rat liver microsomes. Hence, further optimization was required for the discovery of FLT3 inhibitors, with a focus on improving metabolic stability. Compound 16d, which had structural modifications of the methyl group at the 5-position and the 4-(2-methylaminoethoxy) phenyl group at the 6-position, exhibited good inhibitory activity against FLT3 and showed effective antiproliferative activity against four leukemia cell lines, including MV4-11. Moreover, compound 16d displayed enhanced metabolic stability. The results of this study indicated that 16d could be a promising compound for further optimization and development as a potent FLT3 inhibitor.

NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel thienopyrimidine derivative having an excellent anti? inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. The compound according to the present invention strongly inhibits IKB kinase-β (IKK-β) involved in the activation of a transcriptional factor, NF-κB, which is associated with inducing various immune and inflammatory diseases, whereby a composition comprising the compound is a useful therapeutic agent against inflammatory diseases, in particular, arthritis and cancer.